Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tarsus Pharmaceuticals (TARS) Interest & Investment Income (2020 - 2025)

Historic Interest & Investment Income for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to $4.1 million.

  • Tarsus Pharmaceuticals' Interest & Investment Income fell 14.56% to $4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.4 million, marking a year-over-year increase of 766.12%. This contributed to the annual value of $15.0 million for FY2024, which is 4524.52% up from last year.
  • According to the latest figures from Q3 2025, Tarsus Pharmaceuticals' Interest & Investment Income is $4.1 million, which was down 14.56% from $4.2 million recorded in Q2 2025.
  • Over the past 5 years, Tarsus Pharmaceuticals' Interest & Investment Income peaked at $4.2 million during Q2 2025, and registered a low of $7000.0 during Q2 2021.
  • For the 5-year period, Tarsus Pharmaceuticals' Interest & Investment Income averaged around $2.3 million, with its median value being $2.6 million (2023).
  • As far as peak fluctuations go, Tarsus Pharmaceuticals' Interest & Investment Income plummeted by 9440.99% in 2021, and later skyrocketed by 1762500.0% in 2022.
  • Tarsus Pharmaceuticals' Interest & Investment Income (Quarter) stood at $12000.0 in 2021, then soared by 17625.0% to $2.1 million in 2022, then surged by 40.01% to $3.0 million in 2023, then rose by 22.46% to $3.6 million in 2024, then increased by 12.81% to $4.1 million in 2025.
  • Its Interest & Investment Income stands at $4.1 million for Q3 2025, versus $4.2 million for Q2 2025 and $3.5 million for Q1 2025.